somatrogon


( Last Updated : April 5, 2021)
Generic Name:
somatrogon
Project Status:
Active
Therapeutic Area:
Growth hormone deficiency
Manufacturer:
Pfizer Canada ULC
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0683-000

Details


Manufacturer Requested Reimbursement Criteria1:
​Long-term treatment of pediatric patients who have growth hormone deficiency.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openApril 05, 2021
Call for patient/clinician input closedMay 28, 2021
Clarification:

- No patient input submission received

Submission receivedJune 03, 2021
Submission acceptedJune 17, 2021
Review initiatedJune 18, 2021
Draft CADTH review report(s) provided to sponsor for commentSeptember 02, 2021
Deadline for sponsors commentsSeptember 14, 2021
CADTH responses on draft review report(s) provided to sponsorOctober 15, 2021
Expert committee meeting (initial)October 27, 2021
Draft recommendation issued to sponsorNovember 08, 2021
To
November 10, 2021